Glaukos (GKOS)
(Delayed Data from NYSE)
$141.75 USD
+2.42 (1.74%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$141.75 USD
+2.42 (1.74%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Zacks News
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y
by Zacks Equity Research
Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More
by Debanjana Dey
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why Glaukos (GKOS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Glaukos (GKOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos
by Zacks Equity Research
Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
by Zacks Equity Research
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Why Is Glaukos (GKOS) Down 8.7% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -88.64% and 7.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights McKesson, AmerisourceBergen, LHC Group and Glaukos
by Zacks Equity Research
McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.
Medical Device Stocks' Earnings on Aug 3: MCK, ABC & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.
Teleflex (TFX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
by Zacks Equity Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.